Maaike Schilperoort

Maaike Schilperoort

Auto-generated profile, based on publicly available information

Maaike Schilperoort

Department of Medicine, Columbia University Irving Medical Center, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Nature Reviews Cardiology
Verified
Journal Article
Open access
PDF file
WCWei Chen
Wei Chen
MSMaaike Schilperoort
Maaike Schilperoort
Yihai CaoYihai Cao
Yihai Cao
JSJinjun Shi
Jinjun Shi
ITIra Tabas
Ira Tabas
WTWei Tao
Wei Tao
Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis and contribute to the development of novel diagnostic and therapeutic strategies to further reduce the risk of cardiovascular disease. Macrophages have key roles in atherosclerosis progression and, therefore, macrophage-associated pathological processes are important targets for both diagnostic imaging and novel therapies for atherosclerosis. In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in atherosclerotic plaques with the use of rationally designed nanoparticles. We review the latest progress in nanoparticle-based imaging modalities that can specifically target macrophages. Using novel molecular imaging technology, these modalities enable the identification of advanced atherosclerotic plaques and the assessment of the therapeutic efficacy of medical interventions. Additionally, we provide novel perspectives on how macrophage-targeting nanoparticles can deliver a broad range of therapeutic payloads to atherosclerotic lesions. These nanoparticles can suppress pro-atherogenic macrophage processes, leading to improved resolution of inflammation and stabilization of plaques. Finally, we propose future opportunities for novel diagnostic and therapeutic strategies and provide solutions to challenges in this area for the purpose of accelerating the clinical translation of nanomedicine for the treatment of atherosclerotic vascular disease.

9 May 2023 in Immunological Reviews
Verified
Journal Article
Closed access
MSMaaike Schilperoort
Maaike Schilperoort
DNDavid Ngai
David Ngai
SSSantosh Reddy Sukka
Santosh Reddy Sukka
KAKleopatra Avrampou
Kleopatra Avrampou
HSHongxue Shi
Hongxue Shi
ITIra Tabas
Ira Tabas

16 February 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
MSMaaike Schilperoort
Maaike Schilperoort
DNDavid Ngai
David Ngai
MKMarina Katerelos
Marina Katerelos
DPDavid A. Power
David A. Power
ITIra Tabas
Ira Tabas

17 January 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MSMaaike Schilperoort
Maaike Schilperoort
ADAndrea D van Dam
Andrea D van Dam
GHGeerte Hoeke
Geerte Hoeke
ISIrina G. Shabalina
Irina G. Shabalina
AOAnthony Okolo
Anthony Okolo
Mark ChristianMark Christian
Mark Christian
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

10 October 2019 in Journal of Pineal Research
Verified
Journal Article
Open access
PDF file
MSMaaike Schilperoort
Maaike Schilperoort
RBRosa van Den Berg
Rosa van Den Berg
LBLaura A. Bosmans
Laura A. Bosmans
BOBram W. van Os
Bram W. van Os
MDMartijn E. T. Dollé
Martijn E. T. Dollé
SKSander Kooijman
Sander Kooijman
Disruption of circadian rhythm by means of shift work has been associated with cardiovascular disease in humans. However, causality and underlying mechanisms have not yet been established. In this study, we exposed hyperlipidemic APOE*3‐Leiden.CETP mice to either regular light‐dark cycles, weekly 6 hours phase advances or delays, or weekly alternating light‐dark cycles (12 hours shifts), as a well‐established model for shift work. We found that mice exposed to 15 weeks of alternating light‐dark cycles displayed a striking increase in atherosclerosis, with an approximately twofold increase in lesion size and severity, while mice exposed to phase advances and delays showed a milder circadian disruption and no significant effect on atherosclerosis development. We observed a higher lesion macrophage content in mice exposed to alternating light‐dark cycles without obvious changes in plasma lipids, suggesting involvement of the immune system. Moreover, while no changes in the number or activation status of circulating monocytes and other immune cells were observed, we identified increased markers for inflammation, oxidative stress, and chemoattraction in the vessel wall. Altogether, this is the first study to show that circadian disruption by shifting light‐dark cycles directly aggravates atherosclerosis development.

15 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CKCanan Kasikara
Canan Kasikara
MSMaaike Schilperoort
Maaike Schilperoort
BGBrennan Gerlach
Brennan Gerlach
CXChenyi Xue
Chenyi Xue
XWXiaobo Wang
Xiaobo Wang
ITIra Tabas
Ira Tabas
Efferocytosis, the process through which apoptotic cells (ACs) are cleared through actin-mediated engulfment by macrophages, prevents secondary necrosis, suppresses inflammation, and promotes resolution. Impaired efferocytosis drives the formation of clinically dangerous necrotic atherosclerotic plaques, the underlying etiology of coronary artery disease (CAD). An intron of the gene encoding PHACTR1 contains rs9349379 (A>G), a common variant associated with CAD. As PHACTR1 is an actin-binding protein, we reasoned that if the rs9349379 risk allele G causes lower PHACTR1 expression in macrophages, it might link the risk allele to CAD via impaired efferocytosis. We show here that rs9349379-G/G was associated with lower levels of PHACTR1 and impaired efferocytosis in human monocyte–derived macrophages and human atherosclerotic lesional macrophages compared with rs9349379-A/A. Silencing PHACTR1 in human and mouse macrophages compromised AC engulfment, and Western diet–fed Ldlr–/– mice in which hematopoietic Phactr1 was genetically targeted showed impaired lesional efferocytosis, increased plaque necrosis, and thinner fibrous caps — all signs of vulnerable plaques in humans. Mechanistically, PHACTR1 prevented dephosphorylation of myosin light chain (MLC), which was necessary for AC engulfment. In summary, rs9349379-G lowered PHACTR1, which, by lowering phospho-MLC, compromised efferocytosis. Thus, rs9349379-G may contribute to CAD risk, at least in part, by impairing atherosclerotic lesional macrophage efferocytosis.